Cost analysis of secondary prophylaxis with oral clodronate versus pamidronate in metastatic breast cancer patients

Supportive Care in Cancer

Volumn 12, Issue 12, 2004, Pages 844-851

  Romanus, Dorothy ^a,b,e   Iscoe, Neill ^c   DeAngelis, Carlo ^a,b   Shear, Neil ^c,d   Einarson, Thomas R ^a,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^e DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Clodronate; Cost analysis; Metastatic breast cancer; Pamidronate; Secondary prophylaxis

Indexed keywords

CLODRONIC ACID; PAMIDRONIC ACID;

ADULT; BONE METASTASIS; BREAST CANCER; CANADA; CANCER CENTER; CANCER MORTALITY; CANCER PATIENT; CONTROLLED STUDY; COST BENEFIT ANALYSIS; FEMALE; FOLLOW UP; HEALTH CARE COST; HUMAN; INCIDENCE; LIFESPAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REVIEW; SENSITIVITY ANALYSIS; STATISTICAL SIGNIFICANCE;

ANTIMETABOLITES; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; CHI-SQUARE DISTRIBUTION; CLODRONIC ACID; COST-BENEFIT ANALYSIS; DIPHOSPHONATES; FEMALE; HUMANS; MIDDLE AGED; STATISTICS, NONPARAMETRIC;

EID: 12144284227     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-004-0659-5     Document Type: Review

References (13)

1. Hortobagyi G, Theriault R, Lipton A, Porter L, Blayney D, Sinoff C, et al (1998) Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol 16:2038-2044
2. Theriault R, Lipton A, Hortobagyi G, Leff R, Gluck S, Stewart J, et al (1999) Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. J Clin Oncol 17:846-854
3. Breast Cancer Disease Site Group (2003) Use of bisphosphonates in patients with bone metastases from breast cancer. CCO Practice Guideline Initiative. (cited 18 Sept 2003). http://www.cancercare.on.ca/pdf/pebc1-11f.pdf
4. Hillner B, Weeks J, Desch C, et al (2000) Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol 18:72-79
5. Coyte PC, Dobrow MJ, Broadfield L (2001) Incremental cost analysis of ambulatory clinic and home-based intravenous therapy for patients with multiple myeloma. Pharmacoeconomics 19:845-854
6. Statistics Canada (2003) Consumer price index, annual average, health care. Statistics Canada (cited 12 Sep 2003]. http://www.statcan.ca/cgi-bin/ downpub/pickpub.cgi?zru=83030&zre=D4uUo UeeZXw
7. Drummond M, O'Brien B, Stoddard G, et al (1997) Methods for the economic evaluation of health care programmes, 2nd edn. Oxford University Press, New York
8. Goodwin P, Feld R, Evans W, et al (1988) Cost-effectiveness of cancer chemotherapy: an economic evaluation of a randomized trial in small-cell lung cancer. J Clin Oncol 6:1537-1547
9. Ontario Ministry of Health (1998) Ontario Health Insurance Plan. Schedule of Benefits. Kingston, ON
10. Earle C, Coyle D, Smith A, et al (1997) The cost of radiotherapy at an Ontario regional cancer centre. Eur J Cancer 33:S4
11. Canadian Coordinating Office for Health Technology Assessment (1997) Guidelines for economic evaluation of pharmaceuticals: Ottawa, Canada, 2nd edn. Canadian Coordinating Office for Health Technology Assessment (CCOHTA)
12. Beusterien KM, Hill MC, Ackerman SJ, et al (2001) The impact of pamidronate on inpatient and outpatient services among metastatic breast cancer patients. Support Care Cancer 9:169-176
13. Dranitsaris G, Hsu T (1999) Cost utility analysis of prophylactic pamidronate for the prevention of skeletal related events in patients with advanced breast cancer. Support Care Cancer 7:271-279